Biotech - Spark Newswire

1 minute read

Altimmune’s ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%

Today, 3:22 PM

Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study is currently being conducted in Australia.

ALT

1 minute read

MannKind – United Therapeutics’ Formulated Treprostinil Under FDA Review For Pulmonary Hypertension

By Vandana Singh

Today, 3:22 PM

MannKind Corporation (NASDAQ:MNKD) and United Therapeutics Corporation (NASDAQ:UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI…

MNKD

1 minute read

BioCryst Announces Acceptance And Accelerated Review Of The ORLADEYO Marketing Application By The Israeli Ministry Of Health

By Bill Haddad

Today, 3:22 PM

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with

BCRX

1 minute read

Trevena Announces NIH Has Resumed Recruiting Patients In Proof-Of-Concept Study For TRV734 In Opioid Use Disorder

By Bill Haddad

Today, 3:22 PM

Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that NIDA has resumed

TRVN

2 minute read

Freeline Doses Second Patient Of Phase 1/2 MARVEL-1 Clinical Trial For Fabry Disease

By Bill Haddad

Today, 3:22 PM

Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the

FRLN

4 minute read

Altimmune Announces Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers; Weight Loss Of 5.4% Achieved At 6 Weeks With 1.8 mg Once Weekly Dose

By Bill Haddad

Today, 3:22 PM

Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment target Ascending multi-dose regimen well-tolerated without

ALT

1 minute read

RAPT Therapeutics Raises $125M Via Equity At 6% Discount

By Vandana Singh

Today, 3:22 PM

RAPT Therapeutics Inc (NASDAQ:RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents…

RAPT

1 minute read

Protagonist Therapeutics Secures $115M Via Equity Raise

By Vandana Singh

Today, 3:22 PM

Protagonist Therapeutics Inc (NASDAQ:PTGX) priced its previously announced underwritten public offering of around 3 million common shares to raise gross proceeds…

PTGX

1 minute read

Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment

By Vandana Singh

Today, 3:22 PM

Spero Therapeutics Inc (NASDAQ:SPRO) initiated two Phase 1 trials of SPR206, including bronchoalveolar lavage (BAL) trial assessing the penetration of…

SPRO